Non-opioid Pain Patch Market Expected to Reach US$ 4.9 Billion in 2024: North America to be the most lucrative region by 2024

The global Non-Opioid Pain Patch Market was valued at US$ 3.7 Bn in 2015, expected to reach US$ 4.9 Bn by 2024, registering a CAGR of 3.3% during 2016-2024.  Non-opioid pain patches offer efficient transdermal drug delivery option for the treatment of various pain conditions for a prolonged period of time. These include highly popular prescription drug classes such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), counter-irritant analgesics that block the pain sensation by inhibiting the prostaglandins, especially for nociceptive pain. However, the non-opioid pain patches overcome the systemic side effects, mainly gastrointestinal, associated with these drug classes, through their topical action on pain. The construction of patches is done through different technologies including but not limited to dot – matrix patches, hydrohesive or gel reservoir patches, and yet to be introduced TEPI patches. Several manufacturers are focused in introduction of new and effective drugs by conversion of therapeutics into transdermal patches, especially some natural extract products like capsaicin, menthol, and camphor.

The demand for next-generation of trailblazing products that offer the efficient and controlled drug delivery with lower systemic side effects continues to rise in the global non-opioid pain patch market. Introduction of Over-The-Counter pain patches by conversion of prescription oral drugs which offer prolonged pain relief, along with focus on emerging regions for market penetration by creating awareness about the availability of transdermal treatment options for pain relief are major drivers for the global non-opioid pain patch market.

In 2015, the lidocaine patches segment dominated the global non-opioid pain patch market among the patch type segment. However, this segment is expected to encounter a decrease in its market share due to availability of generic lidocaine pain patches. The methyl salicylate patches segment is expected to register higher CAGR during the forecast period of 2016-2024. The major reasons for the high growth rates of these segments during the forecast period is due to its fast pain relief action for longer duration, lesser side effects, and increasing number of methyl salicylate patch manufacturers. The increasing incidence rate of various pain conditions, especially in the Asia Pacific region, and adoption of transdermal drug delivery method are expected to steer the growth of patch type segment. Several new product launches such as ibuprofen patch are expected to change the dynamics of the global non-opioid pain patch market.

The distribution channel segment in the global non-opioid pain patch market include hospital pharmacies, online pharmacies, and independent pharmacies & drug stores. Hospital pharmacies dominated the global non-opioid pain patch market in 2015, owing to ease of access especially in the emerging countries, better provision of healthcare facilities, and greater availability of non-opioid pain patches. The online pharmacies segment is expected to register high CAGR during the forecast period, due to convenience, increasing use of electronic payment technology, expanded range of available medications and services, along with transparency in medicines rates/prices. The increasing focus of various independent organizations along with regional governments on the awareness about the pain management treatments, is expected to propel the growth of the global non-opioid pain patch market during 2016-2024.

Geographically, in 2015 North America dominated the global non-opioid pain patch market due to higher adoption of advanced products and techniques, along with high acute and chronic pain prevalence rate. Europe accounted for the second largest share of the global non-opioid pain patch market in 2015, however Asia Pacific is expected to register highest CAGR during the forecast period owing to number of factors such as increasing demand for better healthcare facilities, high patient pool for pain conditions, and increasing awareness about the pain management treatment in the Asia Pacific region.

Major players having presence in the global non-opioid pain patch market include Acorda Therapeutics, Inc., ALLERGAN, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co.,Inc., IBSA Institut Biochimque SA, Mylan N.V. , Pfizer, Inc., TEH SENG Pharmaceutical Mfg. Co., Ltd., and Teikoku Seiyaku Co., Ltd., among others.

Inquire for a Sample Copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26168

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

No comments.

Leave a Reply

You must be logged in to post a comment.